Melbourne-based Genetic Technologies (ASX:GTG) has listed its Level II American Depositary Receipts (ADRs) on the US Nasdaq national market. [ + ]

Dr Richard Opara, a substantial shareholder in biotech companies Polartechnics (ASX:PLT) and Avantogen (ASX:ACU), is trying to raise money for a new start-up capital biotech fund, but is finding the going tough in Australia and may have to go overseas to find the cash. [ + ]

The fastest and cheapest way yet of identifying and tracking the bugs that cause major human infections is being trialled at Queensland University of Technology (QUT).

South Australian genomics company Bionomics (ASX:BNO) has received a notice of allowance for a US patent, forming part of the company's patent portfolio covering a diagnostic test for severe forms of childhood epilepsy. [ + ]

Alastair Hood has resigned as a director of Avantogen (ASX:ACU), formerly Australian Cancer Technology, citing increased corporate and travel commitments with his investment company Bluespire as the reason for his departure. [ + ]

Tissue-engineering biomedical company Clinical Cell Culture (ASX:CCE, C3) has posted record revenues of AUD$1.4 million, up 51 per cent in the 18 month period from January 1, 2004 to June 30, 2005 (2003: $0.95 million). [ + ]

The Bio21 Molecular Medicine Informatics Model (Bio21:MMIM) is one of nine projects to share $19.4 million in recent funding from the Australian government under the Systemic Infrastructure Initiative (SII). [ + ]

Researchers at Melbourne's Peter MacCallum Cancer Centre have begun testing a high-precision, antibody-mediated system to deliver short-range radionuclides to cancerous cells. [ + ]

Cancer therapy developer Meditech (ASX:MTR) has received an AusIndustry Commercial Ready Grant worth $2.988 million over the next three years towards the development and commercialisation of HyCAMP, its lead anti-cancer product which is in phase II clinical testing. Meditech has also reported a half year loss of $1.68 million and a cash balance of $3.4 million. [ + ]

Norwood Abbey (ASX:NAL) has raised AUD$13.3 million (US$10 million) through US institutional investors to make the final payment on its products used in vision correction surgery and to expand production. [ + ]

Stalled negotiations relating to Avantogen's (ASX:ACU) US$3 million instalment in its $5 million bid to acquire US vaccine developer Regalen, formerly Galenica Pharmaceuticals, may have caused its share price to slide from $0.19 on August 24 to $0.14 on August 31, the company said today in response to an ASX query. [ + ]

Melbourne-based tissue engineering group Kryocor, which planned to close its IPO on March 31 and list on the ASX on April 14, has postponed its float and is considering its options. [ + ]

An 'action agenda' for the Australian science industry -- encompassing 47,000 manufacturers, distributors, laboratory services providers and researchers -- was launched in Sydney yesterday by the minister for industry, tourism and resources, Ian Macfarlane. [ + ]

US artificial heart firm HeartWare (ASX:HTW) has successfully commenced its animal studies by implanting its Miniaturised Ventricular Assist Device (MVAD) in a calf. [ + ]

Queensland University spin-out Nanomics BioSystems has released its first product based on its proprietary second-generation ceramic nanoparticle technology. [ + ]